Hypertension and diastolic heart failure

被引:14
作者
Gradman A.H. [1 ]
Travis Wilson J. [1 ]
机构
[1] Division of Cardiovascular Disease, Western Pennsylvania Hospital, Pittsburgh, PA 15224
关键词
Heart Failure; Left Ventricular Hypertrophy; Diastolic Dysfunction; Diastolic Function; Candesartan;
D O I
10.1007/s11886-009-0061-5
中图分类号
学科分类号
摘要
In patients with hypertension, pressure overload leads to left ventricular hypertrophy (LVH), myocardial fibrosis, and impaired diastolic filling without systolic dysfunction. Presently, diastolic heart failure accounts for about 50% of the heart failure population. Fatigue, dyspnea, reduced exercise tolerance, and peripheral edema are common presenting complaints. As a group, patients with diastolic heart failure are older and predominantly female. Diuretics are effective for treating congestive symptoms. β Blockers and heart rate-lowering calcium blockers show benefit in smaller studies but have not been evaluated in definitive clinical trials. Renin-angiotensin-aldosterone system blockers reduce blood pressure, LVH, and myocardial fibrosis; however, long-term studies with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers demonstrate little effect on symptoms or survival, and inconsistent effects on heart failure hospitalization. At present, evidence-based treatment includes antihypertensive therapy to reduce progression from hypertension to heart failure. In patients with established heart failure, diuretics and other empiric treatments are used to control symptoms. © 2009 Springer Science+Business Media, LLC.
引用
收藏
页码:422 / 429
页数:7
相关论文
共 46 条
[1]
Jessup M., Abraham W.T., Casey D.E., Et al., 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines, Circulation, 119, pp. 1977-2016, (2009)
[2]
Choudhury L., Gheorghiade M., Bonow R.O., Coronary artery disease in patients with heart failure and preserved systolic function, American Journal of Cardiology, 89, 6, pp. 719-722, (2002)
[3]
Gradman A.H., Alfayoumi F., From left ventricular hypertrophy to congestive heart failure: Management of hypertensive heart disease, Prog Cardiovasc Dis, 48, pp. 326-341, (2006)
[4]
Owan T.E., Hodge D.O., Herges R.M., Jacobsen S.J., Roger V.L., Redfield M.M., Trends in prevalence and outcome of heart failure with preserved ejection fraction, New England Journal of Medicine, 355, 3, pp. 251-259, (2006)
[5]
Owan T.E., Redfield M.M., Epidemiology of diastolic heart failure, Progress in Cardiovascular Diseases, 47, 5, pp. 320-332, (2005)
[6]
Gaasch W.H., Zile M.R., Left ventricular diastolic dysfunction and diastolic heart failure, Annual Review of Medicine, 55, pp. 373-394, (2004)
[7]
Redfield M.M., Heart failure with normal ejection fraction, Braunwald's Heart Disease, (2008)
[8]
Masoudi F.A., Havranek E.P., Smith G., Fish R.H., Steiner J.F., Ordin D.L., Krumholz H.M., Gender, age, and heart failure with preserved left ventricular systolic function, Journal of the American College of Cardiology, 41, 2, pp. 217-223, (2003)
[9]
Smith G.L., Masoudi F.A., Vaccarino V., Radford M.J., Krumholz H.M., Outcomes in heart failure patients with preserved ejection fraction: Mortality, readmission, and functional decline, Journal of the American College of Cardiology, 41, 9, pp. 1510-1518, (2003)
[10]
Zile M.R., Brutsaert D.L., New concepts in diastolic dysfunction and diastolic heart failure: Part I: Diagnosis, prognosis, and measurements of diastolic function, Circulation, 105, 11, pp. 1387-1393, (2002)